Package 51267-890-99

{"route": ["ORAL"], "spl_id": "8e7e5582-7a35-4ec7-85e7-b88a98d1bd23", "openfda": {"upc": ["0351267890997"], "unii": ["ZG7E5POY8O", "Z6375YW9SF"], "rxcui": ["1551468", "1551474"], "spl_set_id": ["485ff360-32c8-11df-928b-0002a5d5c51b"], "manufacturer_name": ["Nalpropion Pharmaceuticals LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": true, "description": "7 TABLET, EXTENDED RELEASE in 1 BOTTLE (51267-890-07)", "package_ndc": "51267-890-07", "marketing_start_date": "20210114"}, {"sample": false, "description": "120 TABLET, EXTENDED RELEASE in 1 BOTTLE (51267-890-99)", "package_ndc": "51267-890-99", "marketing_start_date": "20141022"}], "brand_name": "Contrave Extended-Release", "product_id": "51267-890_8e7e5582-7a35-4ec7-85e7-b88a98d1bd23", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Aminoketone [EPC]", "Dopamine Uptake Inhibitors [MoA]", "Increased Dopamine Activity [PE]", "Increased Norepinephrine Activity [PE]", "Norepinephrine Uptake Inhibitors [MoA]", "Opioid Antagonist [EPC]", "Opioid Antagonists [MoA]"], "product_ndc": "51267-890", "generic_name": "naltrexone hydrochloride and bupropion hydrochloride", "labeler_name": "Nalpropion Pharmaceuticals LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Contrave", "brand_name_suffix": "Extended-Release", "active_ingredients": [{"name": "BUPROPION HYDROCHLORIDE", "strength": "90 mg/1"}, {"name": "NALTREXONE HYDROCHLORIDE", "strength": "8 mg/1"}], "application_number": "NDA200063", "marketing_category": "NDA", "marketing_start_date": "20141022", "listing_expiration_date": "20261231"}